Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

  • ID: 3845324
  • Clinical Trials
  • Region: Global
  • 1153 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • MORE
Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

Summary

“Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016" provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • MORE
List of Tables

List of Figures

Report Guidance

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Five Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Renal Cell Carcinoma Therapeutics Clinical Trials

Prominent Drugs

Latest Clinical Trials News on Renal Cell Carcinoma

Aug 04, 2016: Gene expression profile may ID renal cell carcinoma pts unlikely to benefit from nivolumab

Jul 08, 2016: Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma

Jun 06, 2016: Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity

Jun 06, 2016: Calithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting

Jun 05, 2016: Long-Term Survival and Improvement in Quality of Life Observed with Opdivo (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting

Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

Jun 05, 2016: Tyrogenex Presents Data Informing Phase II and Supporting Potential Efficacy of X-82 with Everolimus in Patients with Solid Tumors at the ASCO Annual Meeting 2016

Jun 05, 2016: BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting

May 26, 2016: AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

May 23, 2016: Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma

May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About us

Contact Us

Disclaimer

Source

List of Tables

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*

Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016*

Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*

Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*

Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016*

Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*

Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015

Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*

Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016*

Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*

Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*

Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016*

Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*

Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015

Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

Methodology
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Pfizer Inc.
Novartis AG
Bayer AG
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Bristol-Myers Squibb Company
Merck & Co., Inc.
AstraZeneca Plc
Eisai Co., Ltd.
Amgen Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll